Lopinavir + Ritonavir Tablets

Therapeutic Indication

HIV-1 infection (in combination therapy)

Boosted protease inhibitor regimen for viral suppression

Long-term HIV management

+91 85919 78885

Lopinavir + Ritonavir

Tablet

Lopinavir is a protease inhibitor that prevents HIV viral replication. Ritonavir acts both as a protease inhibitor and as a pharmacokinetic enhancer, boosting Lopinavir’s plasma concentration by inhibiting CYP3A4 metabolism. Together, they form a fixed-dose combination widely used in HIV treatment regimens.

Speciality	Protease Inhibitor Combination Antiretroviral
Tags	HIV \| Antiretroviral \| Protease Inhibitor \| Combination Therapy
Strength	Lopinavir 200 mg Ritonavir 50 mg
Packing Size	10 or 30 Tablets need to confirm

Check all Tablets Range

Click to know More

Mechanism

Lopinavir inhibits HIV protease, preventing cleavage of viral polyproteins and halting viral replication. Ritonavir enhances Lopinavir’s bioavailability by inhibiting CYP3A4 metabolism, ensuring sustained therapeutic levels.

Pharmacokinetics

Absorption: Oral, enhanced with food
Distribution: Widely distributed
Metabolism: Hepatic via CYP3A4
Elimination: Primarily fecal
Half-life: 5–6 hours

Side Effects

Nausea and diarrhea
Abdominal pain
Liver enzyme elevation
Lipid abnormalities

Contraindication

Severe hepatic impairment
Hypersensitivity to Lopinavir or Ritonavir

Interaction

Strong CYP3A4 inhibition — interacts with antibiotics, antifungals, statins, anticoagulants
Requires careful monitoring with other antiretrovirals

Warning and Precautions

Monitor liver function regularly
Check lipid profile during therapy
Use cautiously with multiple drug regimens